Status
Conditions
Treatments
About
The primary objective of this study is to identify immunometabolic signatures associated with Long COVID in plasma and peripheral blood mononuclear cells (PBMC).
Full description
The mechanisms underlying Long COVID remain poorly understood. Among the symptoms most frequently reported by patients with long COVID, some (fatigue, neurocognitive disorders, muscular weakness) are similar to those reported by patients with innate or acquired abnormalities in energy metabolism, suggesting that metabolic changes could play a role in the disease. On the other hand, other studies have shown that COVID-19 induces an immune dysregulation that could persist after recovery.
The hypothesis of this study is that there are subtle but detectable immunometabolic changes in plasma and PBMC of patients with long COVID. The identification of these specific signatures would help to better understand the physiopathology of this disease and to identify possible therapeutic strategies .
The primary objective of this study is to identify immunometabolic signatures in plasma and peripheral blood mononuclear cells (PBMC) of patients with long COVID, as compared to patients who recovered from COVID-19 without prolonged symptoms.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
A/ Inclusion Criteria:
For all patients:
For patient with Long COVID :
For COVID-19 recovered patient (Control) :
B/ Exclusion Criteria:
History of severe COVID-19 (Hospitalization)
Symptoms caused by sequelae of SARS-CoV-2 infection (in particular, persistence of lung parenchymal abnormalities : pulmonary fibrosis, persistent alveolitis on CT-Scan)
Significant Depression or anxiety symptoms, as assessed by a > 10 score on the A or D items of the Hospital anxiety and depression scale (HAD)
Presence of one of the following diseases:
Pregnant, breastfeeding or parturient women
Deprivation of liberty by judicial or administrative decision
Mandatory Psychiatric Care
Protected by decision of law
Unable to express consent
Primary purpose
Allocation
Interventional model
Masking
100 participants in 2 patient groups
Loading...
Central trial contact
Vincent DUBEE, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal